KDR and neoplasm: The circumstances leading to further treatment response when using cabozantinib as a second-line treatment are not completely understood, but they could be related to c-MET inhibition, as previous VEGFR inhibition induces c-MET-driven resistance [31,122], as VEGFR inhibition can lead to hypoxia, which may lead to enhancements in c-MET expression, thus enhancing tumor invasion [29,70].